

FORM PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket No.: AVIGEN-04082

Serial No.: 09/470,618

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**  
(Use Several Sheets If Necessary)

(37 CFR § 1.98(b))

Applicant: Couto *et al.*

Filing Date: 12/22/99

Group Art Unit: 1633

**DOCUMENTS** (Including Author, Title, Date, Relevant Pages, Place of Publication)

DAU	1	Connelly <i>et al.</i> , "Complete Short-Term Correction of Canine Hemophilia A by In Vivo Gene Therapy," <i>Blood</i> 88(10):3846-3853 (1996)
	2	Connelly <i>et al.</i> , "Sustained Phenotypic Correction of Murine Hemophilia A by In Vivo Gene Therapy," <i>Blood</i> 91(9):3273-3281 (May 1, 1998)
	3	Lozier <i>et al.</i> , "Gene Therapy and the Hemophilias," <i>JAMA</i> 271(1):47-51 (1994)
	4	Snyder <i>et al.</i> , "Persistent and Therapeutic Concentrations of Human Factor IX in Mice after Hepatic Gene Transfer of Recombinant AAV Vectors," <i>Nature Genetics</i> 16:270-276 (July 1997)
Y	5	Zatloukal <i>et al.</i> , "In vivo production of human factor VIII in mice after intrasplenic implantation of primary fibroblasts transfected by receptor-mediated, adenovirus-augmented gene delivery," <i>Proc. Natl. Acad. Sci. USA</i> 91:5148-5152 (1994)

Examiner:

Date Considered:

10/31/00

**EXAMINER:**

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.